Tropical spastic paraparesis is a specific type of leg weakness found in certain tropical regions. It's caused by a virus called HTLV-1. It leads to slow-growing weakness in the legs, stiffness, and problems with reflexes and sensation. It's important to get diagnosed and treated early.
Every report comes from a Lived member, sent anonymously.
Have you tried Baclofen for Tropical Spastic Paraparesis?
Tropical spastic paraparesis is a long-term disease of the spinal cord caused by a virus called HTLV-1 (human T-cell lymphotropic virus type 1). Today it is usually called HTLV-1-associated myelopathy, or HAM/TSP. "Myelopathy" means damage to the spinal cord, and "spastic paraparesis" describes what people notice most: legs that become stiff, tight and weak, so walking gradually takes more effort. The condition typically starts in adulthood, often between the ages of 40 and 50. Along with stiff, weak legs, many people have bladder problems such as urgency, frequent urination at night or difficulty emptying the bladder, as well as lower back pain and numbness or tingling in the legs. Bowel function can also be affected. The older name reflects where it was first described, in tropical regions, but HAM/TSP occurs wherever people with HTLV-1 live.
HAM/TSP develops in a small minority of people who carry HTLV-1. The virus infects a type of white blood cell and stays in the body for life. It spreads through breastfeeding, sex, blood transfusion and shared needles. It is most common in southwestern Japan, the Caribbean, parts of South America (especially Brazil), West and Central Africa and parts of the Middle East. In the United States, blood donations have been screened since 1988, which has nearly eliminated spread through transfusion. Most people with HTLV-1 never develop HAM/TSP. Estimates of the lifetime risk range from about a quarter of a percent to a few percent, depending on the region studied. The damage is thought to come from the body's own immune response: immune cells reacting to infected cells inflame the spinal cord over time. People with a higher amount of virus in their blood are more likely to develop the condition, although many people with high levels never do. Why some carriers are affected and others are not is still not fully understood.
Diagnosis starts with the pattern of symptoms and a neurological examination, which typically shows stiff legs, brisk reflexes and weakness. A blood test looks for antibodies to HTLV-1, and a positive screening test is confirmed with a second, more specific test, since a positive result alone shows infection, not disease. A lumbar puncture (spinal tap), in which a small sample of the fluid around the spinal cord is collected, helps link the symptoms to the virus. Finding HTLV-1 antibodies or viral genetic material in this fluid, especially at higher levels than in the blood, strongly supports HAM/TSP. The fluid may also show signs of inflammation. An MRI of the spine and brain often shows a thinned spinal cord, but its main job is to rule out conditions that can look similar, such as spinal cord compression or multiple sclerosis. Clinicians often time a short walk, such as 10 meters, to measure walking speed and track change over the following months.
There is no treatment that clears HTLV-1 or reverses existing spinal cord damage. Care aims to slow the disease when it is getting worse and to ease symptoms. How much treatment makes sense depends largely on how fast the condition is progressing, and the evidence behind all disease-modifying options is limited, coming mostly from small, observational studies. Corticosteroids, which calm inflammation, are the main option for people whose walking is declining. A short course of high-dose intravenous methylprednisolone over 3 to 5 days can improve movement or pain within days, but the effect usually fades over several months. For slowly worsening disease, a low daily dose of prednisolone or prednisone (about 5 mg) taken for up to several years may help hold walking ability steady. People whose condition is getting worse quickly may need higher doses first. Because steroids weaken immune defenses, people are tested beforehand for infections that steroids could make dangerous, including a gut parasite called Strongyloides, tuberculosis, HIV and hepatitis. Long-term use also needs monitoring of bone health, blood sugar and blood pressure, and steroids should not be stopped suddenly. For people whose symptoms are stable over years, specialists generally recommend watchful waiting rather than steroids. Other medicines have been tried. Interferon-alpha, an immune-modifying injection, is licensed for HAM/TSP in Japan but gives mainly short-lived benefit with frequent side effects. HIV-type antiretroviral medicines have not been shown to help. Newer antibody treatments, such as mogamulizumab, are being studied in clinical trials, and specialists encourage people to consider joining one. Symptom care makes a large difference to daily life. Physical therapy helps maintain strength, balance and mobility, and occupational therapy helps with daily tasks and home adaptations. Muscle-relaxing medicines such as baclofen or tizanidine can ease stiffness and spasms. Drowsiness is common, and baclofen can add to weakness, so doses are adjusted gradually and should not be stopped suddenly. Bladder medicines such as oxybutynin can reduce urgency, and some people learn to use a catheter at intervals to empty the bladder fully. Nerve pain may be treated with medicines such as gabapentin or certain antidepressants, and psychological support helps many people adjust to a long-term condition.
HAM/TSP usually worsens slowly over years, but the course varies widely. Some people have mild walking or bladder changes that stay stable for many years, while a smaller group loses the ability to walk within months. Over time, many people need a cane, walker or wheelchair; in long-term studies, about half needed a wheelchair within 20 years of their first symptoms. The condition is rarely fatal, and most people live for decades after diagnosis. Day to day, stiffness, fatigue, bladder urgency and pain often shape routines more than the diagnosis itself. Regular physical activity, planning around bathroom access and adapting the home can help preserve independence. Preventing urinary tract infections and pressure sores on the skin is an important part of staying well, especially as mobility declines. Follow-up visits track walking speed and other measures to see whether the disease is changing and whether treatment is helping. Because HTLV-1 is a lifelong infection, it can also cause other problems, including eye inflammation (uveitis) and, much less often, a blood cancer called adult T-cell leukemia/lymphoma, so ongoing follow-up with clinicians familiar with HTLV-1 is worthwhile.
Arrange an evaluation for walking that is getting stiffer or weaker over time, bladder control problems without a clear cause, or new leg symptoms if you know you carry HTLV-1 or come from a region where it is common. If you already have HAM/TSP, contact your care team promptly if your walking gets noticeably worse over weeks to a few months, such as newly needing a walking aid or a banister on stairs. Rapid decline is when treatment is most urgent and most likely to help. Also contact them about symptoms of a urinary infection, a skin sore that is not healing, new swollen lymph nodes or a new persistent skin rash, or side effects from steroids or other medicines.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Tropical Spastic Paraparesis is like, what's helped you, or ask the community a question.